Clinical trial NCT05832034: Add-on Intravenous Immunoglobulins in Early Myositis
Official title: Treatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEnt
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Inflammatory Myopathy, Idiopathic
Dermatomyositis
Antisynthetase Syndrome
Immune-Mediated Necrotizing Myopathy
Polymyositis
Myositis
Keywords: Myositis
Inflammatory myopathies
Intravenous immunoglobulins
Early symptomatic
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
Collaborators: name: Princess Beatrix Muscle Foundation
First posted: 2023-04-27
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In patients with myositis early immunomodulation by intensive treatment ("hit-early/hit-hard" principle) may induce faster reduction of disease activity and prevent chronic disability. Intravenous immunoglobulin (IVIg) in addition to standard treatment with glucocorticoids may be beneficial for this purpose: add-on IVIg improved symptoms in steroid-resistant myositis, and first-line monotherapy IVIg led to a fast and clinically relevant response in a pilot study in nearly 50% of patients with myositis.

Detailed description: Considering the known effects of IVIg in idiopathic inflammatory myopathies (IIM), both as add-on therapy in refractory patients, as well as monotherapy in newly diagnosed IIM, we conducted a phase-2 double-blind placebo-controlled randomized trial to investigate the effect of add-on IVIg in patients with newly diagnosed IIM, who are treated with monotherapy prednisone.

Objective:

The primary aim of this trial is to examine whether the addition of early administered IVIg to standard therapy with prednisone in patients with newly diagnosed myositis leads to an improved clinical response after 12 weeks, compared to prednisone and placebo. Clinical response will be measured as the difference of the mean TIS after 12 weeks between intervention and control groups.

The secondary aims are to examine whether the intervention leads to a shorter time to improvement, and sustained positive effects on health-related quality of life, physical activity and fatigue, and a sustained reduction of muscle MRI abnormalities, as assessed up to 52 weeks.

Following a screening visit at the outpatient clinic, patients will be admitted to the neurology ward of the Amsterdam University Medical Center (AUMC) for the first infusion of study treatment. The remaining study medication will be administered at home, according to routine clinical practice for IVIg treatment in neuromuscular disorders in the Netherlands. A second and third study treatment will be administered at home after 4 and 8 weeks. At baseline and after 4, 8, 12, 26 and 52 weeks outcome assessments will be performed at the outpatient clinic. The outpatient study clinic visits at baseline and after 4, 12, 26 and 52 weeks will be combined with regular outpatient clinic visits.

The additional burden related to outcome assessments will consist of MRI muscle imaging after 12 weeks, blood sampling after 2, 4, 6, and 10 weeks and filling in questionnaires at baseline and after 4, 8, 12, 26 and 52 weeks. In addition, participants are asked to wear a watch three times in a period of 12 weeks and after 26 weeks.

Eligibility criteria: Inclusion Criteria:

* Adult patients (≥ 18 years) with IIM, according to diagnostic criteria:

  * Dermatomyositis
  * Polymyositis
  * Anti-synthetase syndrome
  * Immune mediated necrotizing myopathy
  * Overlap myositis
* Disease duration \< 12 months
* Minimal disability defined as at least 10% loss on Manual Muscle Testing (MMT) and abnormal scores on two other Core Set Measures (CSMs) of the international Myositis Assessment and Clinical Studies (IMACS) group (see 'Primary and secondary outcomes').
* Patients are eligible for inclusion if they are treatment-naive, or if there is no clinical evident response (as carefully judged by the treating physician at a screening visit) to prior treatment with:
* High dosed glucocorticoids, such as dexamethasone (e.g. 40 mg per day up to 4 days) or intravenous methylprednisolone (e.g. 1000 mg daily for three days), within 1 week prior to screening visit.
* Daily dosed prednisone 1 mg/kg, or equivalent, used for up to 2 weeks prior to screening visit.
* Treatment with low-dosed prednisone (max 20 mg daily) up to three months prior to screening visit.
* Treatment with biologicals or other immunosuppressive or immunomodulatory treatment when meeting all of the following criteria:

  * Stable dose for the last 6 months
  * The biological or other immunosuppressive or immunomodulatory treatment has been approved for a non-muscular condition (e.g. hematological condition, eczema) and is not known for its use in idiopathic inflammatory myopathy
  * The biological or other immunosuppressive or immunomodulatory treatment is not known to induce inflammatory myopathy
* Signed informed consent

Exclusion Criteria:

A potentially eligible patient who meets any of the following criteria will be excluded from participation in this study:

* Severe muscle weakness (i.e. bedridden, severe dysphagia requiring a feeding tube, or respiratory muscle weakness (forced vital capacity below 50% of predicted in upright position)) necessitating more intensive treatment than standard glucocorticoids from the start.
* Related to IVIg:

  * History of thrombotic episodes within 10 years prior to enrolment
  * Known allergic reactions or other severe reactions to any blood-derived product
  * Known Immunoglobulin A (IgA) deficiency and IgA serum antibodies
  * Pregnancy or trying to conceive
  * Use of loop diuretics
  * Use of nephrotoxic medication
* Conditions that are likely to interfere with:

  * Compliance (legally incompetent and/or incapacitated patients are excluded), or,
  * Evaluation of efficacy (e.g. due to severe pre-existing disability as a result of any other disease than myositis or due to language barrier)
* Immunosuppressive medication or immunomodulatory treatment within the last 3 months (e.g. azathioprine, methotrexate, mycophenolate mofetil, tacrolimus, cyclophosphamide, cyclosporine, IVIg, biologicals, Janus kinase inhibitors, plasmapheresis).

Primary outcomes:
measure: Change in Total Improvement Score (TIS)
timeFrame: Baseline and week 12
Secondary outcomes:
measure: Time to response (TIS>40 points)
timeFrame: Will be examined at week 4, 8, 12, 26 and 52 weeks.
measure: Total Improvement Score (IMACS).
timeFrame: TIS will be assessed at t = 0, and after 4, 8, 12, 26 and 52 weeks
measure: Core set measures (CSM) - physician global activity (PhGA)
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Core set measures (CSM) - patient global activity (PGA)
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Core set measures (CSM) - Manual Muscle Testing (MMT)
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Core set measures (CSM) - Health Assessment Questionnaire (HAQ)
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Core set measures (CSM) - Serum muscle enzyme activities
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Core set measures (CSM) - Extramuscular disease activity
timeFrame: CSMs will be assessed at baseline, week 4, 8, 12, 26 and 52.
measure: Patient-Reported Outcome Measures (PROMs) questionnaire - Fatigue
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Patient-Reported Outcome Measures (PROMs) questionnaire - Pain interference
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Patient-Reported Outcome Measures (PROMs) questionnaire - Physical function
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Fatigue
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Health related quality of life (HR-QoL)
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Physical activity
timeFrame: Two consecutive weeks, at baseline, week 4, week 8 and week 26.
measure: Mean daily prednisone dosage
timeFrame: Calculated at week 4, 8, 12, 26 and 52.
measure: Muscle hyperintensities.
timeFrame: At baseline, and after 12 and 26 weeks.
measure: IgG blood levels.
timeFrame: Obtained immediately before, and two weeks after the administration of study medication
measure: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI).
timeFrame: At baseline, and after 4, 8, 12, 26 and 52 weeks.
measure: Composite questionnaire on health care use and productivity loss.
timeFrame: At baseline and week 12
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Department of Neurology, Amsterdam UMC, location AMC
state: North- Holland
Study officials:
affiliation: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
name: Raaphorst, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018 May;14(5):279-289. doi: 10.1038/nrrheum.2018.42. Epub 2018 Mar 29.
citation: Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400.
citation: Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004 May;14(5):337-45. doi: 10.1016/j.nmd.2004.02.006. No abstract available.
citation: Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993 Dec 30;329(27):1993-2000. doi: 10.1056/NEJM199312303292704.
citation: Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L. Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. J Rheumatol. 2019 Jan;46(1):106-111. doi: 10.3899/jrheum.180353. Epub 2018 Sep 15.
citation: Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, Viola S, Buoncompagni A, Mattiuz C, Beltramo A, Consolaro A, Ravelli A, Ruperto N, Picco P, Magnano GM, Martini A. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis. 2014 Jun;73(6):1083-90. doi: 10.1136/annrheumdis-2012-202915. Epub 2013 May 1.
citation: Lim J, Eftimov F, Verhamme C, Brusse E, Hoogendijk JE, Saris CGJ, Raaphorst J, De Haan RJ, van Schaik IN, Aronica E, de Visser M, van der Kooi AJ. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford). 2021 Apr 6;60(4):1784-1792. doi: 10.1093/rheumatology/keaa459.